Analysts Are Bullish on These Healthcare Stocks: Anavex Life Sciences (AVXL), ENDRA Life Sciences (NDRA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), ENDRA Life Sciences (NDRA – Research Report) and Inventiva (IVA – Research Report) with bullish sentiments.

Anavex Life Sciences (AVXL)

BTIG analyst Yun Zhong maintained a Buy rating on Anavex Life Sciences yesterday and set a price target of $28.00. The company’s shares closed last Thursday at $8.32, close to its 52-week low of $7.13.

According to TipRanks.com, Zhong has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -22.8% and a 27.3% success rate. Zhong covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Taysha Gene Therapies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Anavex Life Sciences with a $45.33 average price target, which is a 411.6% upside from current levels. In a report released yesterday, JonesTrading also maintained a Buy rating on the stock with a $58.00 price target.

See today’s best-performing stocks on TipRanks >>

ENDRA Life Sciences (NDRA)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on ENDRA Life Sciences today and set a price target of $9.00. The company’s shares closed last Thursday at $2.60.

According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 14.2% and a 29.7% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Blue Water Vaccines, Inc., Aridis Pharmaceuticals, and Eledon Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ENDRA Life Sciences with a $9.00 average price target.

Inventiva (IVA)

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Inventiva, with a price target of $35.00. The company’s shares closed last Thursday at $3.47.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 21.5% and a 45.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Paratek Pharmaceuticals, Aurinia Pharmaceuticals, and Galmed Pharmaceuticals.

Inventiva has an analyst consensus of Moderate Buy, with a price target consensus of $35.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AVXL:

• ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48-Week Phase 2 Extension Study in Patients with Parkinson’s Disease Dementia
• Anavex appoints Kun Jin as VP, head of biostatistics
• Anavex price target lowered to $28 from $35 at BTIG
• Anavex reports Q1 EPS (17c), consensus (19c)
• Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results